Oral antibiotics and mechanical bowel preparation for colorectal surgery: A prospective observational study of surgical site infection and microbial analysis.
Humans
Anti-Bacterial Agents
/ therapeutic use
Surgical Wound Infection
/ etiology
Metronidazole
/ therapeutic use
Antibiotic Prophylaxis
Colorectal Surgery
RNA, Ribosomal, 16S
Neomycin
/ therapeutic use
Preoperative Care
/ adverse effects
Elective Surgical Procedures
/ adverse effects
Administration, Oral
Cathartics
/ therapeutic use
Abscess
Anastomotic leak
Antibiotics
Colorectal cancer
Infection
Laxatives
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
09 Aug 2023
09 Aug 2023
Historique:
accepted:
29
07
2023
medline:
10
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
epublish
Résumé
Surgical site infections (SSIs) are common in colorectal surgery. Mechanical bowel preparation (MBP) in conjunction with oral antibiotics (OABs) have been shown to reduce SSI rates. It however is still unclear which OABs to use, and how this can be implemented in practice. This is a prospective observational study carried out in Swansea Bay University Health Board during 2019-2021, evaluating the introduction of OABs in a stepwise manner on the incidence of SSI in major colorectal surgery. A control group having MBP only was compared to two OAB groups: one group had MBP plus metronidazole only and the second MBP plus metronidazole and neomycin. A 30-day follow-up after surgery was ascertained via chart review and telephone contact. Logistic regression was performed to estimate the relation between OAB use and SSI, with adjustment for confounding. In a subset of patients, faecal samples were analysed through 16S rRNA amplicon sequencing before and after OAB treatment, depicting the impact of the gut microbiome. In total 160 patients were analysed: 46 patients had MBP only, whilst 76 patients had MBP plus metronidazole only and 38 patients had MBP with metronidazole/neomycin. The SSI rate in the entire cohort was 33.8%, whilst the adjusted ORs for the single- and dual-OAB groups were 0.76 (95% CI: 0.17-1.81) and 0.50 (95% CI: 0.17-1.52). The microbial analysis demonstrated that the relative abundance for many bacterial genera was changed before and after OAB treatment, but no link with SSI development could be shown. Introduction of OABs in conjunction with MBP in colorectal surgery is feasible, and may potentially lead to lower rates of SSI, as well as altering the community structure of the faecal microbiome. More research is needed, especially considering different OABs and mechanistic studies of the gut microbiome in the context of colorectal surgery.
Identifiants
pubmed: 37555867
doi: 10.1007/s00384-023-04497-4
pii: 10.1007/s00384-023-04497-4
pmc: PMC10412473
doi:
Substances chimiques
Anti-Bacterial Agents
0
Metronidazole
140QMO216E
RNA, Ribosomal, 16S
0
Neomycin
I16QD7X297
Cathartics
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
210Subventions
Organisme : Svenska Läkaresällskapet
ID : SLS-934594
Organisme : Cancer Research Foundation in Northern Sweden
ID : AMP 19-978
Organisme : Bengt Ihre's Foundation, Sweden
ID : SLS-934603
Informations de copyright
© 2023. The Author(s).
Références
Ann Surg. 2018 Jun;267(6):1112-1118
pubmed: 28166091
Ann Surg. 2017 Nov;266(5):870-877
pubmed: 28746154
World J Surg. 2019 Mar;43(3):659-695
pubmed: 30426190
Dis Colon Rectum. 2016 Mar;59(3):236-44
pubmed: 26855399
Br J Surg. 2018 Sep;105(10):1368-1376
pubmed: 29658991
BMJ. 2007 Oct 20;335(7624):806-8
pubmed: 17947786
J Clin Oncol. 2021 Jan 1;39(1):66-78
pubmed: 33021869
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834
pubmed: 28650209
J Am Soc Nephrol. 2022 Dec;33(12):2276-2292
pubmed: 36041791
Lancet. 2019 Sep 7;394(10201):840-848
pubmed: 31402112
Genome Med. 2021 Jun 22;13(1):105
pubmed: 34158092
BJS Open. 2018 Oct 15;3(1):106-111
pubmed: 30734021
Colorectal Dis. 2021 May;23(5):1239-1247
pubmed: 33544977
Front Immunol. 2022 Sep 02;13:1008975
pubmed: 36119074
Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Cochrane Database Syst Rev. 2023 Feb 7;2:CD014909
pubmed: 36748942
Lancet Gastroenterol Hepatol. 2020 Aug;5(8):729-738
pubmed: 32325012
Biomedicines. 2021 Sep 09;9(9):
pubmed: 34572371
JAMA Surg. 2017 Aug 01;152(8):784-791
pubmed: 28467526
Br J Surg. 2019 Mar;106(4):355-363
pubmed: 30802304
Gut Pathog. 2017 Oct 26;9:59
pubmed: 29090023
BMJ. 2022 Nov 3;379:e071476
pubmed: 36328372
mSystems. 2019 Nov 12;4(6):
pubmed: 31719139
Am J Infect Control. 2008 Jun;36(5):309-32
pubmed: 18538699
World J Gastroenterol. 2020 Jun 21;26(23):3293-3303
pubmed: 32684743
Clin Infect Dis. 2021 Sep 15;73(6):e1242-e1251
pubmed: 33684930
Nat Commun. 2021 Nov 19;12(1):6757
pubmed: 34799562